関連する実験動画

Updated: Jul 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

FDAは,CAR T細胞受容者の安全性のリスクを調査しています

Roxanne Nelson

    Lancet (London, England)
    |December 10, 2023
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    933
    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    534

    関連する実験動画

    Last Updated: Jul 8, 2026

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.4K
    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    933
    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    534

    関連する概念動画

    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ